PCM
RVMD icon

Prelude Capital Management’s Revolution Medicines RVMD Stock Holding History

Prelude Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.66M Buy
+17,073
New +$1.72M 0.13% 197
2025
Q4 		– Sell
-20,000
Closed -$934K – 1523
2025
Q3 		$934K Buy
+20,000
New +$783K 0.07% 319
2023
Q3 		– Sell
-12,100
Closed -$324K – 1324
2023
Q2 		$324K Buy
+12,100
New +$297K 0.02% 607

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Prelude Capital Management's RVMD Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Revolution Medicines (RVMD) in Q1 2026: 17,073 shares worth $1.66M. The stake represents 0.13% of the portfolio and ranks #197 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in RVMD as recently as Q3 2025.

Prelude Capital Management first reported a position in RVMD in Q2 2023 and has held it in 3 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Prelude Capital Management held 17,073 shares of Revolution Medicines worth $1.66M as of Q1 2026.
  • Revolution Medicines was a new Prelude Capital Management position in Q1 2026.
  • Revolution Medicines made up 0.13% of Prelude Capital Management's portfolio in Q1 2026, its #197 holding.
  • Prelude Capital Management first reported a position in Revolution Medicines in Q2 2023 and has held it in 3 quarters since.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.